within Pharmacolibrary.Drugs.ATC.A;

model A02AB02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A02AB02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Algeldrate (aluminum magnesium carbonate hydrate) is an antacid used to neutralize gastric acid in the stomach. It is employed in the symptomatic treatment of conditions such as dyspepsia and peptic ulcer disease, but is less commonly used today due to the availability of other antacids and acid-suppressing agents.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic models or quantitative PK parameters for algeldrate are available in the scientific literature. As an antacid, algeldrate acts locally in the gastrointestinal tract and is not systemically absorbed.</p><h4>References</h4><ol><li><p>Mroszczak, EJ, et al., &amp; Massey, I (1990). Ketorolac tromethamine pharmacokinetics and metabolism after intravenous, intramuscular, and oral administration in humans and animals. <i>Pharmacotherapy</i> 10(6 ( Pt 2)) 33S–39S. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2082311/&quot;>https://pubmed.ncbi.nlm.nih.gov/2082311</a></p></li><li><p>Gutekunst, L (2016). An Update on Phosphate Binders: A Dietitian&#x27;s Perspective. <i>Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation</i> 26(4) 209–218. DOI:<a href=&quot;https://doi.org/10.1053/j.jrn.2016.01.009&quot;>10.1053/j.jrn.2016.01.009</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26920090/&quot;>https://pubmed.ncbi.nlm.nih.gov/26920090</a></p></li><li><p>Worthington, HV, et al., &amp; Eden, OB (2002). Interventions for treating oral mucositis for patients with cancer receiving treatment. <i>The Cochrane database of systematic reviews</i> None(1) CD001973–None. DOI:<a href=&quot;https://doi.org/10.1002/14651858.CD001973&quot;>10.1002/14651858.CD001973</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11869616/&quot;>https://pubmed.ncbi.nlm.nih.gov/11869616</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A02AB02;
